EGFR and cancer: Tyrosine kinase inhibitors such as osimertinib, erlotinib, and gefitinib target the ERRB/EGFR, and antibodies such as trastuzumab, which target the ecto-domain of ERBB2, have been developed as therapeutics such as ERBB2-overexpressing cancers.